A diabetes medication that lowers brain fluid pressure has cut monthly migraine days by more than half, according to a new study presented today at the European Academy of Neurology (EAN) Congress 2025.1
Researchers at the Headache Center of the University of Naples “Federico II” gave the glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide to 26 adults with obesity and chronic migraine (defined as ≥15 headache days per month). Patients reported an average of 11 fewer headache days…
Continue Reading
News Source: www.sciencedaily.com
Leave a Reply